Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...
On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra ...
Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...
The following is a summary of “Effect of spesolimab on sustained disease control in patients with generalized pustular ...
Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...
Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...
MedPage Today on MSN17h
Rapid, Substantial Psoriasis Improvement With Oral IL-23 InhibitorTwo-thirds of patients with moderate or severe plaque psoriasis had complete or nearly complete clearance at 4 months with an ...
MedPage Today on MSN18h
TYK2 Inhibitor Scores Two Wins Outside Plaque PsoriasisThe TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to ...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced ...
Positive results were reported for Johnson & Johnson's psoriasis drug during.a late-breaking research session today at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback